Investigation of combined phosphodiesterase 5 inhibitor and isosorbide mononitrate for the treatment ofresistant hypertension - Sildenafil and isosorbide mononitrate in resistant hypertensio
- Conditions
- Hypertension
- Registration Number
- EUCTR2005-001004-39-GB
- Lead Sponsor
- niversity of Edinburgh
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 40
?Essential hypertension
?Office BP >140/85 despite treatment with 3 or more antihypertensive agents
?Resistance to treatment proven by directly observed therapy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
?Identifiable underlying cause for hypertension (e.g. Conn’s or Cushing’s syndromes, renal artery stenosis, phaeochromocytoma, coarctation of the aorta)
?Clinically evident coronary artery or cerebrovascular disease
?Taking regular organic nitrates or nicorandil
?Significant renal or liver impairment
?Pregnant
?Current alcohol or drug abuse
?Previous serious drug allergy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: To characterise the effect on blood pressure of a combination of single doses of sildenafil and isosorbide mononitrate in patients with resistant hypertension. ;Secondary Objective: ;Primary end point(s): Effect on blood pressure of the drug combination
- Secondary Outcome Measures
Name Time Method